Online inquiry

IVTScrip™ mRNA-Anti-IL17A, LY2439821(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10406MR)

This product GTTS-WQ10406MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL17A gene. The antibody can be applied in Ankylosing spondylitis (AS) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_002190.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3605
UniProt ID Q16552
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL17A, LY2439821(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ10406MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9068MR IVTScrip™ mRNA-Anti-IGF1R, IMC-A12(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IMC-A12
GTTS-WQ7381MR IVTScrip™ mRNA-Anti-MS4A1, GA101(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA GA101
GTTS-WQ13633MR IVTScrip™ mRNA-Anti-TNFSF4, R4930(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA R4930
GTTS-WQ2914MR IVTScrip™ mRNA-Anti-IL17RA, AMG827(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AMG827
GTTS-WQ13484MR IVTScrip™ mRNA-Anti-IgG-Fc, PRTX-100(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA PRTX-100
GTTS-WQ13908MR IVTScrip™ mRNA-Anti-INHBA, REGN2477(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA REGN2477
GTTS-WQ6918MR IVTScrip™ mRNA-Anti-Alkaline phosphatase substitute, ENB-0040(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ENB-0040
GTTS-WQ15786MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, XmAb-13676(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA XmAb-13676
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW